Literature DB >> 5122222

Determination of glucose by an automatic analyser.

J F Stevens.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1971        PMID： 5122222     DOI： 10.1016/0009-8981(71)90332-9

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN： 0009-8981            Impact factor:   3.786


× No keyword cloud information.
  21 in total

1.  Influence of the insulin sensitive central nervous system glucoregulator receptor on hepatic glucose metabolism.

Authors:  A J Szabo; O Szabo
Journal:  J Physiol       Date:  1975-12       Impact factor: 5.182

2.  Effects of the novel (Pro3)GIP antagonist and exendin(9-39)amide on GIP- and GLP-1-induced cyclic AMP generation, insulin secretion and postprandial insulin release in obese diabetic (ob/ob) mice: evidence that GIP is the major physiological incretin.

Authors:  V A Gault; F P M O'Harte; P Harriott; M H Mooney; B D Green; P R Flatt
Journal:  Diabetologia       Date:  2003-02-12       Impact factor: 10.122

3.  Abnormal plasma glucose and insulin responses in heterozygous lean (ob/+) mice.

Authors:  P R Flatt; C J Bailey
Journal:  Diabetologia       Date:  1981-05       Impact factor: 10.122

4.  Low molecular solutes and the blood cerebrospinal fluid barrier.

Authors:  K Felgenhauer; N Liappis; M Nekic
Journal:  Klin Wochenschr       Date:  1982-11-15

5.  Influence of a transplantable insulinoma on the pancreatic status of insulin and pancreatic polypeptide in the rat.

Authors:  M M O'Hare; C Shaw; S K Swanston-Flatt; M Marcelli; K D Buchanan; P R Flatt
Journal:  Diabetologia       Date:  1985-03       Impact factor: 10.122

6.  Insulin-like effect of pinitol.

Authors:  S H Bates; R B Jones; C J Bailey
Journal:  Br J Pharmacol       Date:  2000-08       Impact factor: 8.739

7.  The effects of streptozotocin diabetes on tissue specific lipase activities in the rat.

Authors:  T Nomura; Y Hagino; M Gotoh; A Iguchi; N Sakamoto
Journal:  Lipids       Date:  1984-08       Impact factor: 1.880

8.  (Pro(3))GIP[mPEG]: novel, long-acting, mPEGylated antagonist of gastric inhibitory polypeptide for obesity-diabetes (diabesity) therapy.

Authors:  P L McClean; N Irwin; K Hunter; V A Gault; P R Flatt
Journal:  Br J Pharmacol       Date:  2008-08-11       Impact factor: 8.739

9.  Evaluation of traditional plant treatments for diabetes: studies in streptozotocin diabetic mice.

Authors:  S K Swanston-Flatt; C Day; C J Bailey; P R Flatt
Journal:  Acta Diabetol Lat       Date:  1989 Jan-Mar

10.  Chemical gastric inhibitory polypeptide receptor antagonism protects against obesity, insulin resistance, glucose intolerance and associated disturbances in mice fed high-fat and cafeteria diets.

Authors:  V A Gault; P L McClean; R S Cassidy; N Irwin; P R Flatt
Journal:  Diabetologia       Date:  2007-06-09       Impact factor: 10.122
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.